[{"id":"a2db800b-7773-424d-82b2-c62ae0087071","acronym":"","url":"https://clinicaltrials.gov/study/NCT05022927","created_at":"2021-08-26T12:53:07.004Z","updated_at":"2024-07-02T16:35:19.713Z","phase":"Phase 1","brief_title":"A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma","source_id_and_acronym":"NCT05022927","lead_sponsor":"Chugai Pharmaceutical","biomarkers":" GPC3","pipe":"","alterations":" ","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • Actemra IV (tocilizumab) • ERY974"],"overall_status":"Recruiting","enrollment":" Enrollment 179","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-02-12"},{"id":"5506a039-637a-4f14-9feb-30df14fa6ca9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02748837","created_at":"2021-03-26T08:15:12.358Z","updated_at":"2024-07-02T16:36:56.662Z","phase":"Phase 1","brief_title":"A Study of ERY974 in Patient With Advanced Solid Tumors","source_id_and_acronym":"NCT02748837","lead_sponsor":"Chugai Pharmaceutical","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERY974"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 08/01/2019","primary_completion_date":" 08/01/2019","study_txt":" Completion: 08/01/2019","study_completion_date":" 08/01/2019","last_update_posted":"2019-08-22"}]